FiscalNote Holdings, Inc. (NOTE): Completion of Acquisition or Disposition of Assets

FiscalNote Holdings, Inc. (NOTE) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 FiscalNote Announces and Completes the Sale of FrontierView to Oxford Economics, Sharpening Focus on Core Policy Business Transaction Further Simplifies the Core Business, Drives Operating Efficiencies, and Strengthens the Balance Sheet FiscalNote Updates Full-Year 2

Original reporting
Published Sep 2, 2026, 8:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 2, 2026, 8:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMergers & acquisitions
Primary signal
$NOTE
Bullish
high confidence
Mentioned
$NOTE
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$NOTEBullishMed
01

Why it matters

The guidance uplift and balance‑sheet improvement may lead to a re‑rating by analysts and a modest price rally.

02

Market read

Primary corporate action for a publicly listed U.S. company with updated financial outlook.

03

What to watch

Details of the transaction price and any earn‑out provisions were not disclosed, leaving valuation impact uncertain.

Relevance 7/10Novelty 7/10Timing: post‑8‑K filing today

Background

FiscalNote filed an SEC Form 8‑K announcing the completion of a divestiture and revised guidance.

Company-level read

Ticker impact

$NOTEBullishHigh confidence
Context

FiscalNote disclosed the sale of its FrontierView business to Oxford Economics and updated full‑year 2026 revenue guidance to $74‑$76 M and adjusted EBITDA to $8‑$10 M.

Expected impact

Potential short‑term upside as investors price in a cleaner business model and higher profitability outlook.

Evidence & confidence

The transaction removes a non‑core segment, updates guidance upward for core operations, and strengthens cash flow, which are typically viewed favorably by the market.

Market effects

Highlights consolidation trend in policy‑intelligence SaaS space, may prompt peers to evaluate non‑core assets.

U.S. tech‑focused investors may adjust exposure to niche data‑analytics firms.

Limited to FiscalNote and similar policy‑data providers.

Counterpoint

The sale could signal underlying weakness in FrontierView's growth prospects, potentially offsetting balance‑sheet benefits.

Key entities

  • FiscalNote Holdings, Inc.

    Provider of AI‑driven policy and regulatory intelligence.

  • Oxford Economics

    Independent economic advisory firm acquiring FrontierView.

Related articles

$NOTELow

FiscalNote Reports Third Quarter 2026 Financial Results

FiscalNote Holdings, Inc. (NOTE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FiscalNote Reports Third Quarter 2026 Financial Results Adjusted EBITDA Rises to $3.6 Million on Lower Costs; Reaffirms FY26 Guidance and Establishes Q4 2026 Forecast WASHINGTON, D. C. – November 9, 2026 – FiscalNote Holdings, Inc. (OTCID: NOTE) (“FiscalNote” or the

$NOTEMed

FiscalNote Reports Second Quarter 2026 Financial Results

FiscalNote Holdings, Inc. (NOTE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FiscalNote Reports Second Quarter 2026 Financial Results Total Revenue In Line with Guidance; Adjusted EBITDA Slightly Below Guidance; Establishes Q3 2026 Forecast and Revises FY26 Guidance Company To Host Conference Call Today at 5:00 PM ET WASHINGTON, D. C. – Augus

$MXCTHighAI 9/10

MaxCyte To Acquire Akron

MaxCyte (MXCT) agreed to acquire Akron BioProducts for $151.8M, including $105M cash, 20.6M shares, and $20M deferred payments. Akron supplies reagents for cell therapy manufacturing. MaxCyte secured a $75M credit facility. MXCT shares rose 11.54% pre-market.

$CRMDHighAI 8/10

CorMedix to Acquire Heron Assets, Adding Four Products and Targeting Up to $60 Million in Savings

CorMedix (CRMD) will acquire assets from Heron, adding four products and aiming for $60M in savings. Heron may receive up to $55M in additional payments tied to ZYNRELEF's 2028 sales. CorMedix will fund the deal with $70M in cash and a $150M loan. Heron's convertible debt holders will convert debt into CorMedix stock. CorMedix plans to relaunch SUSTOL and focus on APONVIE, with a potential FDA approval for an undisclosed injectable product in 2027.

$MXCTHighAI 9/10

MaxCyte to acquire Akron BioProducts for $151.8 million

MaxCyte (MXCT) agreed to acquire Akron BioProducts for $151.8M, including cash, stock, and deferred payments. Akron is projected to generate $28M revenue and $7-8M EBITDA in 2026. The deal is expected to close by year-end 2026 and nearly double MaxCyte's revenue. MaxCyte secured a $75M credit facility for the acquisition.